

1 **Title:** Effect of Antibiotic and Steroid Treatment on Leptospirosis Outcomes: A Single-Center
2 Retrospective Cohort Study in the Transcarpathian Region of Ukraine

3 **Author names and affiliations.**

4 Pavlo Petakh^{1,2*}, Valentyn Oksenyich^{3*}, Mykhailo Poliakh^{4,5}, Ivan Poliakh⁵, Anton Kohutykh⁵,
5 Oleksandr Kamyshnyi²

6 ¹Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine;

7 ²Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National
8 Medical University, Ternopil, Ukraine;

9 ³Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen,
10 5020 Bergen, Norway;

11 ⁴Department of Pediatrics with Pediatric Infectious Diseases, Uzhhorod National University, 88000
12 Uzhhorod, Ukraine;

13 ⁵Transcarpathian Regional Clinical Infectious Hospital, Uzhhorod, Ukraine;

14 **Corresponding author:** Department of Biochemistry and Pharmacology, Uzhhorod National
15 University, Uzhhorod, Ukraine; pavlo.petakh@uzhnu.edu.ua (P.P.)

16 Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, 5020
17 Bergen, Norway; valentyn.oksenych@uib.no (V.O.)

18

19 **Abstract**

20 Leptospirosis presents a significant health challenge in the Transcarpathian region of Ukraine, with
21 higher incidence rates and mortality compared to national averages. We conducted a retrospective
22 cohort study to investigate the effects of antibiotic and steroid treatments on outcomes in leptospirosis
23 patients. Our analysis of clinical and laboratory data from a single center revealed that dexamethasone
24 showed significant effects on various clinical variables, as did investigated antibiotics. Particularly,
25 direct bilirubin levels emerged as a strong predictor of death. These findings provide valuable insights
26 for clinicians in managing leptospirosis, aiding in outcome prediction and treatment decision-making
27 not only in the Transcarpathian region but globally.

28 **Keywords:** leptospirosis; corticosteroids; outcome; antibiotic; dexamethasone; predictors

29

30

31 **1. Introduction**

32 Leptospirosis, a disease primarily found in tropical regions, is a zoonotic illness transmitted through
33 contact with the urine of animals, particularly rats [1]. Its clinical manifestations range from mild to
34 severe, posing life-threatening consequences. Symptoms often mimic those of other infectious
35 diseases, such as influenza [2]. Severe cases, affecting approximately 5% to 15% of individuals,
36 manifest with acute renal failure, acute respiratory distress syndrome, pulmonary issues, hypotension,
37 icterus, and altered mental status [3-7].

38 In the Transcarpathian region, leptospirosis persists as a prevalent zoonotic disease. Between 2005
39 and 2015, 420 cases were reported, with an incidence three times higher than the national average.
40 The case fatality rate (CFR) for leptospirosis in Transcarpathia averages 12.5%, exceeding the
41 national level of 9.8% [8-10].

42 Analysis reveals a significant increase in the notification rate of leptospirosis in Ukraine in 2023. This
43 surge is primarily attributed to the rising incidence of leptospirosis in Transcarpathia, accounting for
44 150 cases out of the total 433 in Ukraine, and the Ivano-Frankivsk region, contributing 34 cases [11]
45 (Figure 1).

46 Pathogenic *Leptospira*, responsible for the disease, are excreted in the urine of rats, with humans
47 inadvertently becoming hosts and facing potentially life-threatening consequences [7]. Rats,
48 however, remain immune to fatal infection, serving as natural reservoirs. Most human leptospiral
49 infections are either mild or asymptomatic. Those who do develop the illness typically experience an
50 abrupt onset of symptoms, including fever, rigors, myalgias, and headache [6, 9].

51 The disease unfolds in two phases [12]. The initial phase involves an acute febrile bacteraemia lasting
52 2 to 9 days, followed by a period of reduced or no fever and apparent improvement. The second
53 phase, known as the "immune" phase, is characterised by renewed fever and the emergence of
54 complications. Approximately 5%–15% of patients may progress to Weil's disease, with pulmonary
55 involvement being a notable feature (20%–70%) [7]. Pulmonary complications range from mild
56 cough to severe symptoms like haemoptysis and Acute respiratory distress syndrome (ARDS), the
57 latter carrying a high mortality rate of around 50% [13-15].

58 The role of corticosteroids in treating severe leptospirosis, especially in addressing pulmonary
59 complications like ARDS, has been explored in a limited number of studies. The argument posits that
60 multi-organ failure in leptospirosis may result from an overactive immune system rather than the
61 direct effects of the pathogen [16]. Therefore, the use of therapeutic doses of steroids is considered
62 to counteract immune activation, potentially reducing mortality and morbidity in severe leptospirosis
63 cases [17]. However, the efficacy of corticosteroids remains uncertain due to the scarcity of studies.

64 This study aims to investigate the effects of antibiotic and steroid treatment on outcomes in patients
65 diagnosed with leptospirosis within the Transcarpathian Region of Ukraine. Through a retrospective
66 analysis of clinical and laboratory data from a single-center cohort, we aim to assess the impact of
67 these treatments on patient morbidity and mortality rates. Additionally, we aim to explore potential
68 associations between treatment regimens and clinical outcomes, thereby providing significant
69 contributions to the understanding and management of leptospirosis in this geographical area.

70 **2. Material and Methods**

71 *2.1. Study design and diagnostic criteria*

72 We conducted a retrospective single-center cohort study. All medical records were obtained from the
73 Transcarpathian Regional Clinical Infectious Diseases Hospital, Ukraine. Confirmation of diagnosis
74 was determined by the order of the Ministry of Health of Ukraine No. 905 of December 28, 2015.
75 This includes fever or at least two of the following symptoms: chills, headache, myalgia, conjunctival
76 hyperemia, skin and mucous membrane hemorrhages, rash, jaundice, myocarditis, meningitis, kidney
77 failure, respiratory manifestations such as hemoptysis, and laboratory confirmation by Polymerase
78 Chain Reaction (PCR) or MAT (Microscopic Agglutination Test).

79 *Inclusion Criteria:* Patients included in this study met the following criteria: diagnosed with
80 leptospirosis according to the criteria outlined by the Ministry of Health of Ukraine; with medical
81 records available at the Transcarpathian Regional Clinical Infectious Diseases Hospital; confirmed
82 laboratory diagnosis by PCR or MAT; complete clinical and laboratory data for analysis; aged 18
83 years and older; and non-pregnant.

84 *Exclusion Criteria:* Patients were excluded from the study if they met any of the following criteria:
85 incomplete medical records or missing key diagnostic information; incomplete or inconsistent
86 laboratory confirmation results; history of receiving medications that could interfere with the study
87 variables or outcomes; younger than 18 years old; or pregnant.

88 *2.2. Patient Stratification and Grouping*

89 We have grouped these patients into different groups for comparing clinical and laboratory data.
90 Firstly, based on sex, males (n=27) and females (n=11). Secondly, based on steroid treatments, the
91 majority received dexamethasone 8 mg per day (n=29), while a few received methylprednisolone 250
92 mg per day (n=2), and others included patients prescribed prednisolone 1 mg/kg/day or combination
93 steroid types (n=4), with 3 patients not receiving steroids. Next, we grouped the patients based on
94 antibiotic treatment into large groups, i.e. those treated with cephalosporins (n=17), benzylpenicillins
95 (n=8), and others treated with carbapenems or macrolides (n=13). Finally, the patients were also
96 grouped based on outcomes, i.e. 35 survivors and 3 non-survivors.

97 2.3 Statistical analysis

98 Power analysis was conducted to ascertain the appropriate sample size necessary to detect statistically
99 significant effects or differences in our study variables, while maintaining a desired level of statistical
100 power.

101 Quantitative variables following a non-normal distribution were described using the median (Me) and
102 lower and upper quartiles (Q1 – Q3). Categorical data were described using absolute and relative
103 frequencies. Comparisons of three or more groups on a quantitative variable with a distribution
104 differing from normality were made using the Kruskal-Wallis test, with Dunn's criterion and Holm
105 correction applied as a *post hoc* method. The Wilcoxon test was employed for comparing quantitative
106 variables following a non-normal distribution between two matched samples. The Mann-Whitney U-
107 test was used to compare two groups on a quantitative variable with a distribution differing from
108 normality. Frequencies in the analysis of multifield contingency tables were compared using
109 Pearson's chi-square test.

110 ROC analysis was utilized to assess the diagnostic performance of quantitative variables in predicting
111 a categorical outcome. The optimal cut-off value of the quantitative variable was estimated using
112 Youden's J statistic.

113 Statistical significance was determined at $p < 0.05$.

114 3. Results

115 3.1. Descriptive analysis and sex-dependent changes in variables

116 Overall, 38 patients were included in our study, of whom 35 survived and 3 died (7.89%). The socio-
117 demographic and clinical presentations, and laboratory findings of all confirmed patients are shown
118 in Table 1.

119 The 38 patients comprised 27 (71.1%) males and 11 (28.9%) females, with a median age of
120 50.00 years (Table 2). Additionally, we conducted a sex-dependent investigation of clinical and
121 laboratory variables on admission. We found significant changes in Mean Corpuscular Volume
122 (MCV) ($p = 0.002$), with males having 91.00 (88.50 – 94.30) fL and females having 87.00 (83.50 –
123 88.50) fL. Males had statistically higher Alanine Aminotransferase (ALT) levels ($p = 0.0048$) than
124 females, with values of 93.30 (65.20 – 134.15) U/L compared to 61.50 (38.75 – 100.55) U/L,
125 respectively. Similarly, males had higher Aspartate Aminotransferase (AST) levels ($p = 0.020$) at
126 81.30 (54.90 – 148.95) U/L compared to females at 47.00 (30.55 – 73.55) U/L.

127 3.2. Effect of steroid type on clinical and laboratory findings

128 Most patients took dexamethasone, comprising 29 out of 38 patients (76.3%). Additionally,
129 only 2 patients (5.3%) received methylprednisolone. Four patients were administered other types of
130 steroids, while three patients did not receive any steroid treatment during their hospitalization.

131 When we compared laboratory findings before admission and after discharge, we found
132 statistically significant changes only in the group that took dexamethasone. The statistically
133 significant changes were observed in Lymphocytes (LYM) levels (on admission: $0.79 \times 10^9/L$ (0.44
134 – 1.45), on discharge: $2.30 \times 10^9/L$ (1.59 – 2.99), $p < 0.001$), Mid-sized Cells (MID) (on admission:
135 $0.30 \times 10^9/L$ (0.14 – 0.47), on discharge: $0.71 \times 10^9/L$ (0.56 – 0.81), $p = 0.002$), Granulocytes (GRA)
136 levels (on admission: $8.18 \times 10^9/L$ (6.25 – 12.16), on discharge: $6.28 \times 10^9/L$ (5.00 – 7.87), $p = 0.033$),
137 Red Blood Cells (RBC) (on admission: $4.64 \times 10^{12}/L$ (4.17 – 4.91), on discharge: $4.30 \times 10^{12}/L$ (3.63
138 – 4.66), $p = 0.004$), MCV (on admission: 90.00 fL (87.00 – 92.00), on discharge: 93.00 fL (89.00 –
139 95.00), $p = 0.004$), Platelets (PLT) levels (on admission: $123.00 \times 10^9/L$ (68.00 – 182.00), on
140 discharge: $320.00 \times 10^9/L$ (204.00 – 350.00), $p < 0.001$), AST (on admission: 72.30 U/L (37.30 –
141 122.00), on discharge: 41.50 U/L (30.50 – 58.10), $p = 0.016$), Direct bilirubin (on admission: 14.40
142 $\mu\text{mol}/L$ (5.68 – 68.70), on discharge: 10.50 $\mu\text{mol}/L$ (5.70 – 21.20), $p = 0.026$), and Urea levels (on
143 admission: 9.63 mmol/L (8.22 – 23.02), on discharge: 7.80 mmol/L (6.65 – 8.63), $p = 0.005$). All
144 other laboratory parameters such as White Blood Cells (WBC) ($\times 10^9/L$), Erythrocyte Sedimentation
145 Rate (ESR) (mm/hr), Hemoglobin (HGB) (g/L), ALT (U/L), Serum Creatinine ($\mu\text{mol}/L$), glucose
146 (mmol/L), Gamma-Glutamyl Transferase (GGT) (U/L), Total Bilirubin ($\mu\text{mol}/L$), Total Protein (g/L)
147 did not show significant differences between admission and discharge ($p > 0.05$) (Figure 2).

148 *3.3. Effect of antibiotic treatment on clinical and laboratory findings*

149 We divided patients into 3 groups, i.e. those who were prescribed cephalosporins - 17 patients,
150 those who were prescribed benzylpenicillin - 8 patients, and a group receiving alternative
151 antimicrobial therapy - 13 patients. We compared the differences in the same indicators as when
152 comparing the effects of steroids.

153 When comparing laboratory findings before admission and after discharge, we observed
154 statistically significant changes in the LYM ($p=0.002$), MID ($p=0.027$), MCV ($p=0.006$), PLT
155 ($p=0.003$), AST ($p=0.015$), glucose ($p=0.045$), Total Bilirubin ($p=0.009$), Direct bilirubin ($p=0.015$),
156 and Urea ($p=0.013$) for the group treated with cephalosporins. Patients treated with benzylpenicillins
157 exhibited statistically significant changes in LYM ($p=0.039$), MID ($p=0.028$), RBC ($p=0.039$), HGB
158 ($p=0.028$), and PLT ($p=0.039$). Patients receiving alternative antimicrobial therapy experienced
159 significant changes in LYM ($p=0.033$), RBC ($p=0.008$), MCV ($p=0.033$), PLT ($p=< 0.001$), Serum
160 Creatinine ($p=< 0.001$), Direct bilirubin ($p=0.048$), and Urea ($p=0.010$) (Table 3). When we compared
161 the effect of antibiotics and steroids on the length of stay (LoS) and outcomes, we did not find any
162 significant differences across the groups (Figure 3).

163 3.4. Effect of laboratory variables on outcome

164 The non-survivor group had statistically higher serum creatinine levels on admission
165 compared to the survivor group (137.30 [111.80 – 321.90] vs. 541.30 [506.10 – 570.60], $p = 0.032$)
166 and GGT levels (75.60 [49.85 – 125.55] vs. 185.30 [163.75 – 442.35], $p = 0.032$). Total bilirubin
167 levels were significantly higher in the non-survivor group compared to the survivor group (491.60
168 [343.95 – 563.30] vs. 25.90 [11.35 – 82.76], $p = 0.010$), as were direct bilirubin levels (257.10 [199.30
169 – 398.85] vs. 14.40 [5.84 – 53.80], $p = 0.010$). Additionally, urea levels were higher in the non-
170 survivor group (30.80 [30.59 – 38.15] vs. 9.63 [8.20 – 21.25], $p = 0.019$).

171 Moreover, we conducted Receiver Operating Characteristic (ROC) analysis. We found that
172 all variables had 100% sensitivity as potential predictors of death, except for GGT, which had a
173 sensitivity of 66.8%. The specificity was lowest for GGT (77.1%), followed by serum creatinine
174 (85.7%), total bilirubin and urea (both 88.6%), and the highest specificity was for direct bilirubin
175 (91.4%) (Figure 4).

176 4. Discussion

177 The Transcarpathian region experienced a significantly higher notification rate in 2023, with
178 150 out of 433 reported cases originating from this area. Situated in the western part of Ukraine, the
179 region shares borders with Romania, Hungary, Poland, and Slovakia [8]. It sustains an above-average
180 human population density, with 63% residing in rural regions, which may impact notification rates
181 [18].

182 We observed that males had higher levels of transaminases such as AST, ALT, and GGT, but
183 this did not affect outcomes. Our findings align with a study conducted in Germany, which revealed
184 that male patients were more likely than female patients to be hospitalized and exhibit symptoms of
185 severe leptospirosis, including jaundice, renal impairment, and haemorrhage [19].

186 Only four studies were found that investigated the role of steroids in clinical outcomes in
187 leptospirosis. In three of these studies, methylprednisolone was administered at the initiation of
188 treatment, albeit at varying doses. They suggested a potential beneficial role of steroids, particularly
189 in patients with lung involvement [20-22]. However, the study that employed dexamethasone at the
190 initiation failed to show a treatment benefit and, notably, reported an elevated incidence of
191 nosocomial infections [23].

192 In regards to the effect of antibiotics on leptospirosis, we found a newly conducted meta-analysis
193 involving 920 patients and 8 antibiotics. The analysis revealed that six antibiotics resulted in
194 significantly shorter defervescence times compared to the control group. These antibiotics include
195 cefotaxime, azithromycin, doxycycline, ceftriaxone, penicillin, and penicillin or ampicillin. However,
196 antibiotics were not found to be effective in reducing mortality or hospital stays [24].

197 Lastly, concerning factors influencing leptospiral outcomes, we conducted our own meta-
198 analysis of clinical predictors involving 1714 patients with leptospirosis. We found that patients with
199 severe outcomes were more likely to experience dyspnea, oliguria, and hemorrhagic symptoms
200 compared to non-severe patients [9].

201 **5. Conclusions**

202 We observed that dexamethasone had a statistically significant effect on certain clinical variables,
203 such as LYM, MID, GRA, Platelet levels, AST, direct bilirubin, and urea levels. Similarly,
204 cephalosporins showed significant effects on LYM, MID, Platelet, AST, total bilirubin, direct
205 bilirubin, and urea levels. Notably, direct bilirubin levels emerged as one of the strongest predictors
206 of death in leptospirosis, exhibiting high sensitivity and specificity. These findings have implications
207 for clinicians not only in the Transcarpathian region but also for practitioners worldwide.

208 **6. Conflict of Interest**

209 The authors declare that the research was conducted in the absence of any commercial or financial
210 relationships that could be construed as a potential conflict of interest.

211 **7. Funding**

212 This research received no specific grant from any funding agency in the public, commercial, or not-
213 for-profit sectors.

214 **8. Author Contributions**

215 Conceptualization, and writing—original draft preparation, P.P.; writing—review and editing, M.P.,
216 A.K., V.O., I.P.; supervision, O.K.; visualization, O.K., P.P.; All authors have read and agreed to the
217 published version of the manuscript.

218 **9. Institutional Review Board Statement**

219 The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics
220 Committee of Uzhhorod National University (protocol code 5/1 on 30 May 2024).

221 **10. Data Availability Statement**

222 The data presented in this study are available on request from the corresponding author.

223 **11. References**

- 224 [1] Haake DA, Levett PN. Leptospirosis in humans. *J Leptospira leptospirosis*. 2015:65-97.
225 [2] Philip N, Lung Than LT, Shah AM, Yuhana MY, Sekawi Z, Neela VK. Predictors of severe
226 leptospirosis: a multicentre observational study from Central Malaysia. *J BMC Infectious Diseases*.
227 2021;21(1):1-6.

- 228 [3] Spichler AS, Vilaça PJ, Athanazio DA, Albuquerque JO, Buzzar M, Castro B, et al. Predictors
229 of lethality in severe leptospirosis in urban Brazil. *The American journal of tropical medicine and*
230 *hygiene*. 2008;79(6):911.
- 231 [4] Panaphut T, Domrongkitchaiporn S, Thinkamrop B. Prognostic factors of death in
232 leptospirosis: a prospective cohort study in Khon Kaen, Thailand. *International Journal of Infectious*
233 *Diseases*. 2002;6(1):52-9.
- 234 [5] Doudier B, Garcia S, Quennee V, Jarno P, Brouqui PJCM, *Infection*. Prognostic factors
235 associated with severe leptospirosis. *Wiley Online Library*; 2006. p. 299-300.
- 236 [6] Petakh P, Isevyeh V, Mohammed IB, Nykyforuk A, Rostoka L. Leptospirosis: Prognostic
237 Model for Patient Mortality in the Transcarpathian Region, Ukraine. *Vector borne and zoonotic*
238 *diseases (Larchmont, NY)*. 2022;22(12):584-8.
- 239 [7] Petakh P, Isevyeh V, Kamyshnyi A, Oksenyeh V. Weil's Disease-Immunopathogenesis,
240 Multiple Organ Failure, and Potential Role of Gut Microbiota. *Biomolecules*. 2022;12(12).
- 241 [8] Markovych O, Tymchyk V, Kolesnikova I. Leptospirosis in Zakarpattia Oblast (2005–2015).
242 *Vector-Borne and Zoonotic Diseases*. 2019;19(5):333-40.
- 243 [9] Petakh P, Rostoka L, Isevyeh V, Kamyshnyi A. Identifying risk factors and disease severity
244 in leptospirosis: A meta-analysis of clinical predictors. *Tropical doctor*. 2023;53(4):464-9.
- 245 [10] Petakh P, Kamyshnyi A, Tymchyk V, Armitage R. Infectious diseases during the Russian-
246 Ukrainian war - Morbidity in the Transcarpathian region as a marker of epidemic danger on the EU
247 border. *Public Health in Practice*. 2023;6:100397.
- 248 [11] Pavlo P, Viktoriia T, Oleksandr K. Surveillance of human leptospirosis infections in Ukraine
249 between 2018 and 2023 *Front Public Health*. 2024;12.
- 250 [12] Xavier V, Baby B, George JM, Ittyachen AM. Covid-19 and leptospirosis, pulmonary
251 involvement and response to steroids: A comparative observational study from a rural Tertiary care
252 center in Kerala. *Journal of family medicine and primary care*. 2022;11(1):294-8.
- 253 [13] Gulati S, Gulati A. Pulmonary manifestations of leptospirosis. *Lung India : official organ of*
254 *Indian Chest Society*. 2012;29(4):347-53.
- 255 [14] Dolhnikoff M, Mauad T, Bethlem EP, Carvalho CRR. Pathology and pathophysiology of
256 pulmonary manifestations in leptospirosis. *J Brazilian Journal of Infectious Diseases*.
257 2007;11(1):142-8.
- 258 [15] Vieira SR, Brauner JS. Leptospirosis as a cause of acute respiratory failure: clinical features
259 and outcome in 35 critical care patients. *The Brazilian journal of infectious diseases : an official*
260 *publication of the Brazilian Society of Infectious Diseases*. 2002;6(3):135-9.
- 261 [16] Limothai U, Lumlertgul N, Sirivongrangson P, Kulvichit W, Tachaboon S, Dinhuzen J, et al.
262 The role of leptospiremia and specific immune response in severe leptospirosis. *J Scientific reports*.
263 2021;11(1):1-9.

- 264 [17] Petakh P, Nykyforuk A. Predictors of lethality in severe leptospirosis in Transcarpathian
265 region of Ukraine. *Le infezioni in medicina*. 2022;30(2):272-6.
- 266 [18] Wasiński B, Dutkiewicz J. Leptospirosis-current risk factors connected with human activity
267 and the environment. *Annals of agricultural and environmental medicine : AAEM*. 2013;20(2):239-
268 44.
- 269 [19] Jansen A, Stark K, Schneider T, Schöneberg I. Sex differences in clinical leptospirosis in
270 Germany: 1997-2005. *Clinical infectious diseases : an official publication of the Infectious Diseases*
271 *Society of America*. 2007;44(9):e69-72.
- 272 [20] Ittyachen M A, Vkl, Ck E, Joseph M. Methylprednisolone as adjuvant in treatment of acute
273 respiratory distress syndrome owing to leptospirosis - A pilot study. *Indian Journal of Critical Care*
274 *Medicine (ISSN: 0972-5229) Vol 9 Num 3*. 2005;9.
- 275 [21] Kularatne SA, Budagoda BD, de Alwis VK, Wickramasinghe WM, Bandara JM, Pathirage
276 LP, et al. High efficacy of bolus methylprednisolone in severe leptospirosis: a descriptive study in Sri
277 Lanka. *Postgraduate medical journal*. 2011;87(1023):13-7.
- 278 [22] Shenoy VV, Nagar VS, Chowdhury AA, Bhalgat PS, Juvale NI. Pulmonary leptospirosis: an
279 excellent response to bolus methylprednisolone. *Postgraduate medical journal*. 2006;82(971):602-6.
- 280 [23] Niwattayakul K, Kaewtasi S, Chueasuwanchai S, Hoontrakul S, Chareonwat S, Suttinont C,
281 et al. An open randomized controlled trial of desmopressin and pulse dexamethasone as adjunct
282 therapy in patients with pulmonary involvement associated with severe leptospirosis. *Clinical*
283 *microbiology and infection : the official publication of the European Society of Clinical Microbiology*
284 *and Infectious Diseases*. 2010;16(8):1207-12.
- 285 [24] Ji Z, Jian M, Su X, Pan Y, Duan Y, Ma W, et al. Efficacy and safety of antibiotics for treatment
286 of leptospirosis: a systematic review and network meta-analysis. *Systematic reviews*. 2024;13(1):108.
- 287

288 **Table 1.** Demographic and Clinical Characteristics of Patients with Leptospirosis in the
 289 Transcarpathian Region of Ukraine

| | Abs. | % |
|---------------------|------|------|
| Sex | | |
| Male | 27 | 71.1 |
| Female | 11 | 28.9 |
| Serogroups | | |
| Hebdomadis | 10 | 26.3 |
| Canicola | 4 | 10.5 |
| Clinical | 3 | 7.9 |
| Others | 2 | 5.3 |
| Pomona | 3 | 7.9 |
| Sejroe | 5 | 13.2 |
| Icterohaemorrhagiae | 3 | 7.9 |
| Cynopteri | 7 | 18.4 |
| Australis | 1 | 2.6 |
| Outcome | | |
| Survive | 35 | 92.1 |
| Non-survive | 3 | 7.9 |
| Antibiotic | | |
| Cephalosporins | 17 | 44.7 |
| Benzylpenicillins | 8 | 21.1 |
| Others | 13 | 34.2 |
| Steroids | | |
| None | 3 | 7.9 |
| Dexamethasone | 29 | 76.3 |
| Methylprednisolone | 2 | 5.3 |
| Others | 4 | 10.5 |

290

291

292

293 **Table 2.** Clinical and Laboratory Findings at Admission for Patients with Leptospirosis

| Variables | Median (Me) | Q₁ – Q₃ (Interquartile Range) |
|--|--------------------|--|
| Age (years) | 50.00 | 44.25 – 63.75 |
| Length of Stay (LoS) (days) | 10.00 | 7.00 – 11.75 |
| WBC ($\times 10^9/L$) | 10.73 | 6.87 – 14.81 |
| LYM ($\times 10^9/L$) | 0.71 | 0.43 – 1.45 |
| MID ($\times 10^9/L$) | 0.31 | 0.14 – 0.63 |
| GRA ($\times 10^9/L$) | 8.18 | 6.25 – 13.38 |
| ESR (mm/hr) | 46.50 | 30.00 – 75.25 |
| RBC ($\times 10^{12}/L$) | 4.38 | 4.08 – 4.91 |
| HGB (g/L) | 128.00 | 113.50 – 140.75 |
| MCV (fL) | 89.50 | 87.00 – 92.00 |
| PLT ($\times 10^9/L$) | 116.50 | 68.00 – 181.25 |
| ALT (U/L) | 92.15 | 55.00 – 128.85 |
| AST (U/L) | 76.15 | 44.52 – 123.35 |
| Serum Creatinine ($\mu\text{mol}/L$) | 138.90 | 112.67 – 421.27 |
| Glucose (mmol/L) | 7.28 | 6.55 – 9.04 |
| GGT (U/L) | 85.75 | 52.62 – 157.88 |
| Total Bilirubin ($\mu\text{mol}/L$) | 34.00 | 12.47 – 121.80 |
| Direct Bilirubin ($\mu\text{mol}/L$) | 19.35 | 6.22 – 91.58 |
| Total Protein (g/L) | 61.20 | 55.25 – 63.27 |
| Urea (mmol/L) | 10.82 | 8.26 – 23.08 |

294

295

296 **Table 3.** Effect of Antibiotics on Laboratory Findings

| Variables | Group | On Admission (Median [Q1 – Q3]) | On Discharge (Median [Q1 – Q3]) | P value |
|----------------------------|--------------------|------------------------------------|------------------------------------|----------|
| WBC ($\times 10^9/L$) | Cephalosporins | 8.39 (6.59 – 14.01) | 9.25 (7.86 – 12.86) | 0.747 |
| | Benzylopenicillins | 9.87 (7.49 – 12.73) | 8.96 (6.77 – 11.04) | 0.844 |
| | Others | 11.68 (7.12 – 18.00) | 9.62 (7.31 – 12.08) | 0.414 |
| LYM ($\times 10^9/L$) | Cephalosporins | 0.62 (0.39 – 1.20) | 2.50 (1.68 – 3.02) | 0.002* |
| | Benzylopenicillins | 0.60 (0.43 – 0.86) | 1.73 (1.25 – 1.91) | 0.039* |
| | Others | 1.18 (0.53 – 2.14) | 2.05 (1.58 – 2.81) | 0.033* |
| MID ($\times 10^9/L$) | Cephalosporins | 0.24 (0.14 – 0.39) | 0.68 (0.43 – 0.81) | 0.027* |
| | Benzylopenicillins | 0.34 (0.29 – 0.51) | 0.84 (0.54 – 1.09) | 0.028* |
| | Others | 0.36 (0.13 – 0.99) | 0.71 (0.62 – 0.75) | 0.497 |
| GRA ($\times 10^9/L$) | Cephalosporins | 7.39 (6.15 – 12.16) | 6.73 (5.08 – 8.71) | 0.109 |
| | Benzylopenicillins | 8.46 (6.70 – 11.77) | 6.03 (5.00 – 7.95) | 0.250 |
| | Others | 8.54 (6.25 – 15.20) | 6.94 (4.70 – 7.87) | 0.094 |
| ESR (mm/hr) | Cephalosporins | 40.00 (27.00 – 63.00) | 33.00 (20.00 – 60.00) | 0.378 |
| | Benzylopenicillins | 63.50 (31.50 – 79.25) | 51.50 (34.50 – 75.25) | 0.641 |
| | Others | 59.00 (41.00 – 82.00) | 49.00 (41.00 – 70.00) | 0.127 |
| RBC ($\times 10^{12}/L$) | Cephalosporins | 4.48 (4.24 – 5.01) | 4.33 (3.89 – 4.93) | 0.207 |
| | Benzylopenicillins | 4.01 (3.80 – 4.80) | 3.67 (3.56 – 4.07) | 0.039* |
| | Others | 4.38 (4.16 – 4.80) | 4.37 (3.46 – 4.50) | 0.008* |
| HGB (g/L) | Cephalosporins | 130.00 (123.00 – 140.00) | 125.00 (116.00 – 144.00) | 0.782 |
| | Benzylopenicillins | 121.50 (112.75 – 127.25) | 115.50 (112.00 – 117.75) | 0.028* |
| | Others | 127.00 (110.00 – 142.00) | 127.00 (102.00 – 138.00) | 0.340 |
| MCV (fL) | Cephalosporins | 90.00 (87.00 – 92.00) | 92.00 (89.00 – 94.00) | 0.006* |
| | Benzylopenicillins | 90.00 (86.75 – 93.00) | 91.50 (88.50 – 95.25) | 0.250 |
| | Others | 89.00 (87.00 – 95.00) | 90.00 (88.00 – 97.00) | 0.033* |
| PLT ($\times 10^9/L$) | Cephalosporins | 136.00 (73.00 – 229.00) | 346.00 (293.00 – 398.00) | 0.003* |
| | Benzylopenicillins | 85.00 (49.75 – 150.50) | 174.50 (132.25 – 338.50) | 0.039* |
| | Others | 107.00 (68.00 – 139.00) | 278.00 (228.00 – 339.00) | < 0.001* |
| ALT (U/L) | Cephalosporins | 93.00 (41.60 – 169.30) | 85.40 (64.40 – 106.80) | 0.159 |
| | Benzylopenicillins | 85.65 (68.72 – 247.22) | 68.50 (62.27 – 132.75) | 0.250 |

| | | | | |
|---------------------------|-------------------|-----------------------------|-----------------------------|----------|
| | Others | 85.30 (53.80 – 120.60) | 55.90 (41.10 – 98.50) | 0.839 |
| AST (U/L) | Cephalosporins | 81.30 (39.10 – 135.80) | 49.30 (34.50 – 58.10) | 0.015* |
| | Benzylpenicillins | 69.80 (48.12 – 156.90) | 49.15 (27.60 – 93.25) | 0.109 |
| | Others | 76.20 (44.10 – 103.00) | 37.50 (27.60 – 53.90) | 0.168 |
| Serum Creatinine (µmol/L) | Cephalosporins | 119.70 (107.10 – 243.80) | 105.90 (102.90 – 126.40) | 0.109 |
| | Benzylpenicillins | 264.80 (124.55 – 524.65) | 117.75 (103.17 – 262.07) | 0.461 |
| | Others | 144.10 (115.30 – 437.20) | 109.90 (101.20 – 132.50) | < 0.001* |
| Glucose (mmol/L) | Cephalosporins | 6.59 (6.45 – 7.77) | 6.40 (6.00 – 6.76) | 0.045* |
| | Benzylpenicillins | 8.47 (6.75 – 9.48) | 6.37 (5.88 – 7.86) | 0.109 |
| | Others | 7.80 (6.77 – 9.10) | 6.78 (6.53 – 8.91) | 0.376 |
| GGT (U/L) | Cephalosporins | 120.00 (57.80 – 172.70) | 79.90 (49.10 – 157.60) | 0.064 |
| | Benzylpenicillins | 77.25 (50.67 – 123.05) | 76.70 (45.30 – 110.97) | 0.148 |
| | Others | 74.80 (47.60 – 125.60) | 74.80 (61.70 – 110.00) | 0.735 |
| Total Bilirubin (µmol/L) | Cephalosporins | 25.90 (10.80 – 56.60) | 12.40 (11.10 – 29.20) | 0.009* |
| | Benzylpenicillins | 108.66 (44.82 – 261.20) | 43.35 (31.35 – 176.55) | 0.612 |
| | Others | 20.50 (14.70 – 159.30) | 20.10 (12.70 – 38.80) | 0.080 |
| Direct bilirubin (µmol/L) | Cephalosporins | 14.40 (5.68 – 37.10) | 7.80 (5.40 – 19.40) | 0.015* |
| | Benzylpenicillins | 72.81 (31.20 – 170.40) | 24.30 (17.12 – 99.60) | 0.461 |
| | Others | 11.10 (6.90 – 99.20) | 9.80 (6.90 – 20.50) | 0.048* |
| Total protein (g/L) | Cephalosporins | 58.53 (54.70 – 63.30) | 60.50 (58.60 – 62.30) | 0.469 |
| | Benzylpenicillins | 59.75 (56.23 – 63.06) | 59.53 (54.25 – 61.73) | 0.641 |
| | Others | 62.30 (59.60 – 63.20) | 61.80 (58.80 – 63.00) | 0.244 |
| Urea (mmol/L) | Cephalosporins | 9.63 (8.22 – 20.39) | 7.35 (6.52 – 8.18) | 0.013* |
| | Benzylpenicillins | 20.52 (8.12 – 30.87) | 9.45 (7.56 – 18.40) | 0.945 |
| | Others | 17.45 (8.72 – 23.02) | 7.92 (6.65 – 8.63) | 0.010* |

299 **Figure 1.** Average annual rate of confirmed leptospirosis cases per 100,000 population, European
300 Union/European Economic Area, 2010–2021. Adapted from ECDC [25]. The average number of
301 leptospirosis cases in Ukraine is one of the highest in Europe, amounting to 0.73 per 100,000 people
302 for the period 2010-2021. For comparison, in neighboring countries, the rate is 0.1 in Poland, 0.15 in
303 Slovakia, and 0.34 in Romania.

304 **Figure 2.** Facet box plots of laboratory findings on admission and discharge in patients who took
305 dexamethasone

306 Statistically significant changes were observed in multiple parameters including LYM, MID, GRA,
307 RBC, MCV, PLT, AST, Direct bilirubin, and Urea levels.

308 **Figure 3.** Box plots illustrating the Effect of steroids and antibiotics on Length of Stay (LoS).

309 No significant changes were observed in patients receiving either steroids or antibiotics

310 **Figure 4.** Direct bilirubin levels on admission as a potential predictor of lethality in leptospirosis.

311 A. Box plot illustrating direct bilirubin levels on admission in surviving and non-surviving patients.

312 B. ROC curve depicting the relationship between the probability of outcome and direct bilirubin.

313 C. Analysis of sensitivity and specificity of outcome based on direct bilirubin levels.






Figure 4



Figure 2





Figure 3